News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Why Valeant (VRX) CEO Thinks Johnson & Johnson (JNJ) Should Foot The Bill For Their Talc Defense



5/25/2017 6:41:04 AM

  Life Sciences Jobs  
  • Newest Jobs - Last 24 Hours
  • California Jobs
  • Massachusetts Jobs
  • New Jersey Jobs
  • Maryland Jobs
  • Washington Jobs
  View More Jobs
BRIDGEWATER, NJ — When Valeant, the scandal-ridden pharmaceutical giant, acquired Johnson & Johnson’s Shower to Shower body product in 2012, it didn’t foresee being up against more than 30 lawsuits claiming that talc—an ingredient in the product—could cause cancer.

But news broke on May 9 that Valeant believes J&J is obligated to pay for its legal defense and compensate Valeant, according to a transcript of Valeant’s first quarter earnings call.

Read at News Release


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES